Emergent BioSolutions and PANTHER Back Africa CDC Mpox Study
Emergent BioSolutions is partnering with PANTHER to fund Africa CDC’s MpOx Study in Africa (MOSA), which seeks treatments for mpox a virus with no specific medicine yet.
The trial began in 2024 and is currently running in several African countries, with a focus on the Democratic Republic of Congo. After reviewing early safety data, experts confirmed the study is safe to continue.
Africa CDC and PANTHER plan to expand the study to more countries, including Uganda, and enrol more patients to strengthen Africa’s ability to fight health threats.
Mpox remains a major concern, with over 61,000 cases and nearly 300 deaths reported across 32 African nations since early 2024.
📥 Read the full brief in your preferred language:
👉 English PDF – Africa CDC Weekly Brief | 5 – 11 January 2026
👉 Version française – Bulletin Hebdomadaire d’Africa CDC | 5 – 11 Janvier 2026
🔗 For direct inquiries or media engagement: communications@africacdc.org
